Scholarlink

Background <p>Despite recent advances in glioblastoma (GBM) therapies, patient survival remains dismal. Existing prognostic markers lack sufficient accuracy, and the resistance of GBM to chemotherapy underscores the need for both improved predictive models and new therapeutic targets.</p> Methods <p>We analyzed transcriptomic data from GBM and non-tumor brain tissues in the TCGA and GTEx databases to identify differentially expressed genes (DEGs). A prognostic signature was then constructed via univariate Cox regression, LASSO selection, and multivariate Cox analysis. The resulting prognostic model was validated in an independent GEO GBM cohort using Kaplan–Meier and log-rank testing. We further compared mutation patterns and immune infiltration between high- and low-risk groups. Multi-omics integration highlighted candidate tumor suppressors, which were functionally assessed in GBM cell lines and an orthotopic mouse model for the effects on ferroptosis sensitivity.</p> Results <p>A 14-gene prognostic signature was developed and robustly stratified GBM patients into high- and low-risk groups with significantly different overall survival. High-risk tumors showed elevated <i>PTEN</i> mutation frequency, enhanced immunosuppressive microenvironments with increased PD-L1 and regulatory T cells, and distinct co-mutation patterns. <i>STOX1</i> and <i>ZNF248</i> were remarkably downregulated in GBM tissues. Their overexpression in <i>vitro</i> suppressed GBM cell proliferation and sensitized cells to ferroptosis. In vivo, nude mice bearing <i>STOX1</i>-overexpressing GBM cells showed prolonged survival under ferroptosis-inducing conditions.</p> Conclusion <p>We present a validated 14-gene prognostic model that accurately predicts GBM patient outcomes and reveals <i>STOX1</i> and <i>ZNF248</i> as novel tumor suppressors related to ferroptosis. Targeting <i>STOX1</i> and <i>ZNF248</i> may overcome the resistance of GBM to ferroptosis and improve therapeutic efficacy.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Development and validation of a novel glioblastoma prognostic model: identifying STOX1 and ZNF248 as ferroptosis-related biomarkers

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年12月21日

查看全文
  • Shaowen Wang,
  • Songyu Xing,
  • Kunyu Li,
  • Siyu Liu,
  • Yulu Yang,
  • Xinzhou Zhu,
  • Wai Sang Poon

摘要

Background

Despite recent advances in glioblastoma (GBM) therapies, patient survival remains dismal. Existing prognostic markers lack sufficient accuracy, and the resistance of GBM to chemotherapy underscores the need for both improved predictive models and new therapeutic targets.

Methods

We analyzed transcriptomic data from GBM and non-tumor brain tissues in the TCGA and GTEx databases to identify differentially expressed genes (DEGs). A prognostic signature was then constructed via univariate Cox regression, LASSO selection, and multivariate Cox analysis. The resulting prognostic model was validated in an independent GEO GBM cohort using Kaplan–Meier and log-rank testing. We further compared mutation patterns and immune infiltration between high- and low-risk groups. Multi-omics integration highlighted candidate tumor suppressors, which were functionally assessed in GBM cell lines and an orthotopic mouse model for the effects on ferroptosis sensitivity.

Results

A 14-gene prognostic signature was developed and robustly stratified GBM patients into high- and low-risk groups with significantly different overall survival. High-risk tumors showed elevated PTEN mutation frequency, enhanced immunosuppressive microenvironments with increased PD-L1 and regulatory T cells, and distinct co-mutation patterns. STOX1 and ZNF248 were remarkably downregulated in GBM tissues. Their overexpression in vitro suppressed GBM cell proliferation and sensitized cells to ferroptosis. In vivo, nude mice bearing STOX1-overexpressing GBM cells showed prolonged survival under ferroptosis-inducing conditions.

Conclusion

We present a validated 14-gene prognostic model that accurately predicts GBM patient outcomes and reveals STOX1 and ZNF248 as novel tumor suppressors related to ferroptosis. Targeting STOX1 and ZNF248 may overcome the resistance of GBM to ferroptosis and improve therapeutic efficacy.